Haneda Masakazu, Kikkawa Ryuichi, Sakai Hideto, Kawamori Ryuzo
Second Department of Medicine, Asahikawa Medical College, 1-1-1 Midorigaoka Higashi-Nijyo, Asahikawa, Hokkaido 078-8510, Japan.
Diabetes Res Clin Pract. 2004 Oct;66(1):87-95. doi: 10.1016/j.diabres.2004.02.015.
The effect of the angiotensin II receptor blocker, candesartan cilexetil, on proteinuria was examined in a prospective, multicenter, randomized, double-blind study in Japanese subjects with type 2 diabetes. This study enrolled diabetic subjects with confirmed proteinuria into four groups for 12 weeks of treatment with placebo or candesartan cilexetil 2, 4, or 8 mg. The contribution of the angiotensin converting enzyme (ACE) gene polymorphism to the effect of candesartan cilexetil was also examined. In 127 subjects, candesartan cilexetil showed a dose-related reduction in proteinuria after 12 weeks of treatment (F = 9.45, P = 0.0013), with a 18.1% reduction in the 4-mg group, and a 5.8% reduction in the 8-mg group, in contrast to a 32.2% increase in the placebo group, and a 0.8% increase in the 2-mg group. These results indicate that candesartan cilexetil is useful in reducing proteinuria in diabetic subjects when compared with placebo. In addition, candesartan cilexetil seems to be effective in subjects with both the II and DD genotypes of the ACE gene.
在一项针对日本2型糖尿病患者的前瞻性、多中心、随机、双盲研究中，研究了血管紧张素II受体阻滞剂坎地沙坦酯对蛋白尿的影响。该研究将确诊为蛋白尿的糖尿病患者分为四组，分别接受安慰剂或2毫克、4毫克或8毫克坎地沙坦酯治疗12周。还研究了血管紧张素转换酶（ACE）基因多态性对坎地沙坦酯疗效的影响。在127名受试者中，治疗12周后，坎地沙坦酯使蛋白尿呈剂量依赖性降低（F = 9.45，P = 0.0013），4毫克组降低了18.1%，8毫克组降低了5.8%，而安慰剂组增加了32.2%，2毫克组增加了0.8%。这些结果表明，与安慰剂相比，坎地沙坦酯有助于降低糖尿病患者的蛋白尿。此外，坎地沙坦酯似乎对ACE基因II型和DD型基因型的受试者均有效。
